

Yogen Saunthararajah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7064509/publications.pdf>

Version: 2024-02-01

115
papers

5,134
citations

136740

32
h-index

91712

69
g-index

117
all docs

117
docs citations

117
times ranked

6073
citing authors

#	ARTICLE	IF	CITATIONS
1	Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	15
2	Functional characterization of NPM1-TYK2 fusion oncogene. <i>Npj Precision Oncology</i> , 2022, 6, 3.	2.3	2
3	Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas. <i>International Journal of Cancer</i> , 2022, 151, 1431-1446.	2.3	6
4	Low-dose weekly decitabine and venetoclax in TP53-mutated myeloid malignancies. <i>Journal of Clinical Oncology</i> , 2022, 40, e19005-e19005.	0.8	0
5	Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. <i>Leukemia</i> , 2021, 35, 1023-1036.	3.3	62
6	A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. <i>Seminars in Hematology</i> , 2021, 58, 35-44.	1.8	7
7	Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells. <i>Seminars in Hematology</i> , 2021, 58, 1-3.	1.8	4
8	Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. <i>Leukemia and Lymphoma</i> , 2021, 62, 735-738.	0.6	5
9	DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Seminars in Hematology</i> , 2021, 58, 45-55.	1.8	8
10	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. <i>Leukemia</i> , 2021, 35, 3324-3328.	3.3	2
11	Î²-Hemoglobinopathies lead the way. <i>Blood</i> , 2021, 137, 1567-1569.	0.6	2
12	Functional analyses of human LUC7-like proteins involved in splicing regulation and myeloid neoplasms. <i>Cell Reports</i> , 2021, 35, 108989.	2.9	23
13	Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2649.	1.7	12
14	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1885-1895.	0.6	32
15	Thioredoxin reductase is a major regulator of metabolism in leukemia cells. <i>Oncogene</i> , 2021, 40, 5236-5246.	2.6	11
16	Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression. <i>Leukemia</i> , 2021, 35, 2799-2812.	3.3	41
17	Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions. <i>Clinical Cancer Research</i> , 2021, 27, 6653-6661.	3.2	12
18	A non-cytotoxic regimen of decitabine to treat refractory T-cell large granular lymphocytic leukemia. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04533.	0.2	3

#	ARTICLE	IF	CITATIONS
19	PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation. <i>Cell Reports</i> , 2021, 36, 109747.	2.9	9
20	The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. <i>Blood</i> , 2021, 138, 2781-2798.	0.6	27
21	Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. <i>Leukemia</i> , 2021, , .	3.3	1
22	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. <i>Leukemia</i> , 2020, 34, 957-962.	3.3	32
23	Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. <i>British Journal of Haematology</i> , 2020, 188, 924-929.	1.2	15
24	Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. <i>Communications Biology</i> , 2020, 3, 493.	2.0	30
25	Cytoplasmic dislocation of NPM1 and PU.1 in <i>NPM1</i> -mutated leukaemia is obscured by paraformaldehyde fixation. <i>British Journal of Haematology</i> , 2020, 189, 578-581.	1.2	1
26	Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation. <i>Haematologica</i> , 2020, 105, 2191-2193.	1.7	6
27	A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 3047-3060.	1.4	3
28	Liver background uptake of [¹⁸ F]FLT in PET imaging. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 10, 212-225.	1.0	1
29	[¹⁸ F] Clofarabine for PET Imaging of Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1748.	1.7	4
30	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. <i>Cancer Discovery</i> , 2019, , .	7.7	0
31	Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion. <i>Scientific Reports</i> , 2019, 9, 4558.	1.6	13
32	EZH2 Inhibitors: Take It EZy, It Is All About Context. <i>Cancer Discovery</i> , 2019, 9, 472-475.	7.7	10
33	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. <i>Cancer Discovery</i> , 2019, 9, 778-795.	7.7	41
34	Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation. <i>Annals of Hematology</i> , 2019, 98, 1529-1531.	0.8	4
35	OAS-RNase L innate immune pathway mediates the cytotoxicity of a DNA-demethylating drug. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 5071-5076.	3.3	58
36	CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas. <i>Blood Cancer Journal</i> , 2019, 9, 14.	2.8	3

#	ARTICLE	IF	CITATIONS
37	Targeting sickle cell disease root-cause pathophysiology with small molecules. <i>Haematologica</i> , 2019, 104, 1720-1730.	1.7	15
38	Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1122-1127.	2.0	10
39	A Novel <i>Asparaginase</i> with low <i>-Glutaminase</i> Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias <i>In Vivo</i> . <i>Cancer Research</i> , 2018, 78, 1549-1560.	0.4	67
40	Ultimate Precision: Targeting Cancer but Not Normal Self-replication. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 950-963.	1.8	13
41	Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. <i>Cell Death and Disease</i> , 2018, 9, 912.	2.7	64
42	Fetal Hemoglobin Induction by Epigenetic Drugs. <i>Seminars in Hematology</i> , 2018, 55, 60-67.	1.8	35
43	Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons. <i>Experimental Hematology</i> , 2018, 67, 60-64.e2.	0.2	17
44	Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. <i>Journal of Clinical Investigation</i> , 2018, 128, 4260-4279.	3.9	97
45	Dynamics of clonal evolution in myelodysplastic syndromes. <i>Nature Genetics</i> , 2017, 49, 204-212.	9.4	348
46	Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 2025-2027.	0.2	10
47	5-aza-2,2-Difluoro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer. <i>Pharmaceuticals</i> , 2017, 10, 65.	1.7	7
48	Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase I study. <i>PLoS Medicine</i> , 2017, 14, e1002382.	3.9	107
49	Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 812-824.	1.8	12
50	GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. <i>Journal of Clinical Investigation</i> , 2017, 127, 3527-3542.	3.9	35
51	Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 812-824.	1.8	9
52	Recurrent genetic defects on chromosome 5q in myeloid neoplasms. <i>Oncotarget</i> , 2017, 8, 6483-6495.	0.8	34
53	The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (<i>P. anubis</i>). <i>Haematologica</i> , 2016, 101, 688-697.	1.7	48
54	Prospective Clinical Study of Precision Oncology in Solid Tumors. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	70

#	ARTICLE	IF	CITATIONS
55	Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 574-582.	1.9	14
56	GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation. <i>Cancer Research</i> , 2016, 76, 2743-2753.	0.4	43
57	The Role of LUC7L2 in Splicing and MDS. <i>Blood</i> , 2016, 128, 5504-5504.	0.6	7
58	Pre-clinical proof of principle of pharmacologically rational non-cytotoxic epigenetic-immunotherapy to treat lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14073-e14073.	0.8	0
59	The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice. <i>Blood</i> , 2015, 126, 386-396.	0.6	74
60	iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors. <i>PLoS ONE</i> , 2015, 10, e0135543.	1.1	27
61	Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. <i>Leukemia and Lymphoma</i> , 2015, 56, 497-499.	0.6	19
62	Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. <i>Journal of Clinical Investigation</i> , 2015, 125, 1043-1055.	3.9	79
63	Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing. <i>Blood</i> , 2015, 126, 709-709.	0.6	2
64	A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8584-8584.	0.8	1
65	Decitabine Suspends Human CD34+ Cell Differentiation and Proliferation during Lentiviral Transduction. <i>PLoS ONE</i> , 2014, 9, e104022.	1.1	4
66	Methylation Profiles Reveal Distinct Subgroup of Hepatocellular Carcinoma Patients with Poor Prognosis. <i>PLoS ONE</i> , 2014, 9, e104158.	1.1	94
67	Ligand exchange on gold nanoparticles for drug delivery and enhanced therapeutic index evaluated in acute myeloid leukemia models. <i>Experimental Biology and Medicine</i> , 2014, 239, 853-861.	1.1	18
68	Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts. <i>Journal of Hematology and Oncology</i> , 2014, 7, 89.	6.9	22
69	Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine. <i>Leukemia and Lymphoma</i> , 2014, 55, 447-449.	0.6	19
70	Runx1 Regulation of Pu.1 Corepressor/Coactivator Exchange Identifies Specific Molecular Targets for Leukemia Differentiation Therapy. <i>Journal of Biological Chemistry</i> , 2014, 289, 14881-14895.	1.6	33
71	Subchronic Oral Toxicity Study of Decitabine in Combination With Tetrahydrouridine in CD-1 Mice. <i>International Journal of Toxicology</i> , 2014, 33, 75-85.	0.6	13
72	Ribosomal S6 Kinase and AKT Phosphorylation as Pharmacodynamic Biomarkers in Patients With Myelodysplastic Syndrome Treated With RAD001. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 172-177.e1.	0.2	5

#	ARTICLE	IF	CITATIONS
73	Combination with Thu to Address Pharmacologic Limitations of Decitabine, Interim PK/PD from a Phase 1/2 Clinical Trial of Oral Thu-Decitabine in Sickle Cell Disease. <i>Blood</i> , 2014, 124, 90-90.	0.6	3
74	Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy. <i>Clinical Cancer Research</i> , 2013, 19, 938-948.	3.2	115
75	Gender, Cytidine Deaminase, and 5-Aza/Decitabine Response. <i>Clinical Cancer Research</i> , 2013, 19, 3106-3107.	3.2	8
76	Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 511-521.	0.9	70
77	Splicing Factor 3b Subunit 1 (SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of MitoFerrin-1 (SLC25A37). <i>Blood</i> , 2013, 122, 1555-1555.	0.6	1
78	CEBPE activation in PML-RARA cells by arsenic. <i>Blood</i> , 2012, 119, 2177-2179.	0.6	8
79	Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. <i>Blood</i> , 2012, 119, 1240-1247.	0.6	90
80	Polycomb segment myeloid malignancies. <i>Blood</i> , 2012, 119, 1097-1098.	0.6	12
81	Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1441-1450.	2.0	33
82	SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. <i>Blood</i> , 2012, 120, 3173-3186.	0.6	173
83	Gender effects on cytidine analogue metabolism and myelodysplastic syndrome treatment outcomes. <i>Nature Precedings</i> , 2012, , .	0.1	0
84	High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. <i>Oncotarget</i> , 2012, 3, 1137-1145.	0.8	53
85	Epigenetic regulation by decitabine of melanoma differentiation <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2012, 131, 18-29.	2.3	64
86	p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies. <i>Seminars in Oncology</i> , 2012, 39, 97-108.	0.8	51
87	p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. <i>Nature Precedings</i> , 2011, , .	0.1	1
88	RUNX1 regulates corepressor interactions of PU.1. <i>Blood</i> , 2011, 117, 6498-6508.	0.6	49
89	A pilot study of subcutaneous decitabine in β^2 -thalassemia intermedia. <i>Blood</i> , 2011, 118, 2708-2711.	0.6	73
90	Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease. <i>British Journal of Haematology</i> , 2011, 153, 386-392.	1.2	9

#	ARTICLE	IF	CITATIONS
91	Noncytotoxic Differentiation Treatment of Renal Cell Cancer. <i>Cancer Research</i> , 2011, 71, 1431-1441.	0.4	30
92	Combining Tetrahydrouridine with Decitabine Addresses Malignant Cell Sanctuary in the Liver, a Tissue That Expresses High Levels of Cytidine Deaminase. <i>Blood</i> , 2011, 118, 3509-3509.	0.6	0
93	Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2011, 118, 120-120.	0.6	0
94	Prognostic Factors for Post-Transplant Outcomes in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2011, 118, 2015-2015.	0.6	9
95	Runx1 Haploinsufficiency Permits Lineage-Commitment but Impairs Activation of a Key Late Differentiation Gene. <i>Blood</i> , 2011, 118, 2442-2442.	0.6	0
96	Oral Administration of Low-Dose Decitabine and Tetrahydrouridine In Combination Increases Fetal Hemoglobin to Therapeutic Levels In the Absence of Cytotoxicity and Reduces Inter-Individual Drug Bioavailability In Baboons. <i>Blood</i> , 2011, 118, 2147-2147.	0.6	0
97	Decitabine Maintains Hematopoietic Precursor Self-Renewal by Preventing Repression of Stem Cell Genes by a Differentiation-Inducing Stimulus. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1536-1543.	1.9	50
98	A High Resolution Analysis of Chromosome 21 Amplification In Myeloid Malignancies Reveals An Association with a Specific Cytogenetic Subgroup and Enhanced ERG Gene Expression. <i>Blood</i> , 2010, 116, 1687-1687.	0.6	0
99	Identification of Oncogenic EZH2 Mutations In Myelodysplastic Syndromes and Related Myeloid Malignancies. <i>Blood</i> , 2010, 116, 607-607.	0.6	0
100	Expression of Phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) Is Associated with An Increased Risk of Death In Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 1675-1675.	0.6	0
101	Prognostic Significance of Histone (H4) Acetylation In Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with Intermediate Risk Cytogenetics. <i>Blood</i> , 2010, 116, 2736-2736.	0.6	0
102	Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. <i>Blood</i> , 2009, 113, 1315-1325.	0.6	378
103	Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2009, 114, 1012-1012.	0.6	1
104	The Value of Post-Remission Therapy in Older Adults with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2009, 114, 1043-1043.	0.6	0
105	Strong Histone (H4) Acetylation Is Independently Associated with Better Overall Survival in Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2009, 114, 4681-4681.	0.6	0
106	Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. <i>Blood</i> , 2008, 111, 3991-3997.	0.6	193
107	Differences Between Normal and Leukemic Stem Cell-Specific Methylome Indicates Aberrantly Silenced Genes Involved in the Pathogenesis of Malignant Evolution. <i>Blood</i> , 2008, 112, 599-599.	0.6	3
108	Runx1 Deficiency Produces Aberrant Progenitor Self-Renewal through Selective Compromise of Pu.1 Mediated Transactivation but Not Transrepression. <i>Blood</i> , 2008, 112, 1351-1351.	0.6	0

#	ARTICLE	IF	CITATIONS
109	DNA hypo-methylating agents and sickle cell disease. <i>British Journal of Haematology</i> , 2004, 126, 629-636.	1.2	33
110	Modification of hematopoietic stem cell fate by 5-aza-2'-deoxycytidine and trichostatin A. <i>Blood</i> , 2004, 103, 4102-4110.	0.6	198
111	Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 1645.	3.8	741
112	Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. <i>Blood</i> , 2003, 102, 3865-3870.	0.6	262
113	HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. <i>Blood</i> , 2002, 100, 1570-1574.	0.6	235
114	HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. <i>Blood</i> , 2002, 100, 1570-4.	0.6	75
115	Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. <i>Blood</i> , 2001, 98, 3513-3519.	0.6	135